News

Amprion has been awarded a $100,000 research grant to support studies on the causes of sporadic amyotrophic lateral sclerosis (ALS) that could help diagnose and develop potential therapies for the disease. The project, led by Richard Smith, MD, state director of the Center for Neurologic Study, and Amprion’s…

A man with amyotrophic lateral sclerosis (ALS) recently became the first person to control an Amazon Alexa device with his thoughts, via an investigational, implanted brain-computer interface (BCI) from Synchron. The 64-year-old man, identified in a Synchron press release as Mark, lost the function of his upper…

Certain rare genetic variants associated with Parkinson’s disease and other neurodegenerative disorders may increase, by up to nearly four times, the risk of developing amyotrophic lateral sclerosis (ALS), a study found. These variations also may lead to faster ALS progression and shorter survival, so patients who carry the…

RAG-17, an investigational therapy from Ractigen Therapeutics, was safe and well tolerated across all tested doses in people with amyotrophic lateral sclerosis (ALS) carrying mutations in the SOD1 gene — cases in which the disease is known as SOD1-ALS. Those are the findings of an investigator-initiated trial (NCT05903690)…

Quralis has completed dosing in the first group of healthy adults who volunteered for its Phase 1 clinical trial of QRL-101, an experimental oral small molecule being developed for amyotrophic lateral sclerosis (ALS). QRL-101-03 (NCT06532396) is expected to enroll about 60 volunteers who’ll be divided into five…

NRG Therapeutics has received a grant from the nonprofit Target ALS to advance preclinical studies of its new class of oral small molecules targeting mitochondria, the energy producers of cells, as a potential treatment for amyotrophic lateral sclerosis (ALS). The 2024 In Vivo Target Validation grant program, an…

The U.S. Food and Drug Administration (FDA) has given the green light to Dr.Noah Biotech to initiate a Phase 1 clinical trial of NDC-011, a combination therapy for amyotrophic lateral sclerosis (ALS), in healthy volunteers. The trial, planned for the first half of 2025 at a single site…

AcuraStem has received $4 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance the development of AS-241, an investigational treatment strategy for amyotrophic lateral sclerosis (ALS) and related diseases. AS-241 is an antisense oligonucleotide (ASO), a type of small molecule that binds to RNA…

Measuring the levels of a novel protein biomarker called C-X-C motif chemokine ligand 12 — CXCL12 for short — in the spinal fluid may improve the diagnosis of amyotrophic lateral sclerosis (ALS) by better differentiating it from similar conditions, according to a new study. In particular, the…

A strategy that simultaneously targets motor neurons, astrocytes, and microglia — three cell types involved in the development and progression of amyotrophic lateral sclerosis (ALS) — was shown to further extend survival in a mouse model of the disease. Specifically, targeting the three cell types at the same time…